Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Update: Nirsevimab (Beyfortus) – FAQs for Healthcare Professionals
This update from the Pediatric Pandemic Network (PPN) describes the new guidelines from the CDC with additional recommendations from the FDA, AAP, and AAFP. There …
Ask aRCie
Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization
2024
· Children's National Hospital
This study looks at how respiratory syncytial virus (RSV) affects children in the ICU. It describes that 11.4% of pediatric ICU admissions are due to …
Summer 2023 ACIP Update: RSV Prevention and Updated Recommendations on Other Vaccines
2023
· University of Colorado,
· Children's National Hospital,
· University of South Florida,
· University of Alabama at Birmingham,
· University of Cincinnati,
· Cincinnati Children's Hospital Medical Center
This article describes updates from the Advisory Committee on Immunization Practices (ACIP) about vaccines for children. It highlights new recommendations for using nirsevimab, a monoclonal …
Equitable Access to RSV Prevention: Challenges and Opportunities With Nirsevimab's Rollout
This editorial discusses challenges in achieving equal access to RSV prevention. This includes providing affordable vaccines, educating communities on prevention strategies, and implementing policies that …
Fall 2023 ACIP Update on Meningococcal, RSV, COVID-19, and Other Pediatric Vaccines
2024
· Children's National Hospital,
· University of South Florida,
· University of Alabama at Birmingham,
· University of Colorado,
· University of Cincinnati
This article summarizes updates from the Advisory Committee on Immunization Practices (ACIP), a group advising the CDC, relevant to pediatrics, including recommendations for COVID-19 and …
Nirsevimab Coverage, Children 0 to 7 months, United States
The report describes how nirsevimab coverage for infants 0 to 7 months is tracked in the U.S. using data from Immunization Information Systems (IIS). It …
Assessment of Effectiveness and Impact of Universal Prophylaxis With Nirsevimab for Prevention of Hospitalizations Due to Respiratory Syncytial Virus in Infants. The NIRSE-GAL Study Protocol
2024
· Instituto de Investigación Sanitaria,
· World Health Organization (WHO),
· University of Santiago de Compostela,
· Instituto de Salud Carlos III
The NIRSE-GAL study in Galicia, Spain, aims to assess the effectiveness of nirsevimab in preventing hospitalizations due to Respiratory Syncytial Virus (RSV) in infants. It …
Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children
2024
· University of Michigan,
· Centers for Disease Control and Prevention (CDC),
· U.S. Public Health Service
This study evaluated the cost-effectiveness of using nirsevimab to prevent respiratory syncytial virus (RSV) in infants and high-risk children. By analyzing healthcare data, it was …
Infant Protection Against Respiratory Syncytial Virus (RSV) by Maternal RSV Vaccination or Receipt of Nirsevimab, and Intent for Nirsevimab Receipt, United States [Dataset]
This dataset provides monthly estimates of infant protection against RSV that were calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM). The data …
A Framework for Monitoring RSV Prevention Product Effectiveness in the United States
This article outlines a framework for CDC's RSV immunization effectiveness program, focusing on evaluating current immunization policy, informing future policy, boosting confidence in immunization, and …